MDL Petition Filed for Type 2 Diabetes Drugs Onglyza and Kobiglyze

WASHINGTON, D.C. — Plaintiffs who allege they suffered heart failure after taking Onglyza and Kombiglyze (Saxagliptin) have filed a motion with the Judicial Panel on Multidistrict Litigation, requesting that a centralized docket be established in California for all federal lawsuits involving the Type 2 diabetes drugs.

The October 11 filing refers to more than 40 similar lawsuits filed in two dozen different judicial districts throughout the United States and refers to hundreds of others that are likely to be filed in their wake.

Onglyza and Kombiglyze, which were introduced to the U.S. market in 2009 and 2010, respectively, are designed …